Micvotabart pelidotin (MICVO) + KEYTRUDA® (pembrolizumab)
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) - 2L+ Post EGFRi and/or anti-PD(L)-1
Key Facts
Indication
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) - 2L+ Post EGFRi and/or anti-PD(L)-1
Phase
Phase 1
Status
Active
Company
About Pyxis Oncology
Pyxis Oncology is a public, clinical-stage biotech company dedicated to transforming cancer treatment through a differentiated portfolio of ADCs and immunotherapies. Its innovative approach targets tumor cells and the immunosuppressive tumor microenvironment, with a lead program, MICVO, showing promise in Phase 1 trials for head and neck cancer. The company is led by an experienced management team with a track record in oncology drug development and company building, and is strategically advancing its pipeline both as monotherapies and in combination with established agents like pembrolizumab.
View full company profile